Page 61 - ஐந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) January 25, 2021 Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care Amsterdam, the Netherlands - Royal Philips). The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT together comprised approximately 600 patients in Europe and the U.S. After five years, the ILLUMENATE EU RCT showed 19.3% mortality among patients treated with the Stellarex DCB compared to 19.4% mortality for those treated with PTA. The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA (20.2%). Both studies had a high vital status follow-up compliance, with the status of over 90% of patients known.

Noord hollandPhilips enduracoatPhilips stellarexChris landonMarianne brodmannUniversity of grazPhilips global press officeMedical universitySenior vice presidentGeneral manager image guided therapy devicesImage guided therapyநூற்த் ஹாலண்ட்கிறிஸ் லேண்டன்பல்கலைக்கழகம் ஆஃப் க்ர்யாஸ்பிலிப்ஸ் உலகளாவிய ப்ரெஸ் அலுவலகம்மருத்துவ பல்கலைக்கழகம்